The NHS will divert billions of pounds from essential services to pay for new medicines under the terms of the US-UK trade deal agreed in December, which could lead to more than 200,000 excess deaths, analysis has found.
Trade deal terms and NHS impact
Ministers have defended the deal as a way of helping British drug exports avoid US tariffs and giving patients access to vital medication. However, critics accuse the Labour party of caving into pressure from Donald Trump. The analysis, conducted by independent researchers, indicates that the cost of new medicines will strain NHS budgets, potentially resulting in 200,000 excess deaths over the next decade.
Political reactions and expert opinions
Columnist Aditya Chakrabortty, speaking to Lucy Hough, highlighted the trade-off between trade benefits and public health. According to Chakrabortty, the deal prioritizes pharmaceutical industry profits over patient welfare. The government has not commented on the specific excess death figures but maintains that the agreement will lower drug prices for some treatments.
